Clinical Trial Update: Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories [Phase 2]

View source ↗

Summary

A Phase 2 safety, tolerability, and abuse-liability study of intravenous NRP104 in adults with stimulant-use histories has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amphetamine Use Disorder
• Attention Deficit Hyperactivity Disorder
• Stimulant Use Disorder

Drugs mentioned

• NRP104

Snippet

Sponsor: New River Pharmaceuticals | Conditions: Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders | Phase 2 | Status: COMPLETED